Status:
RECRUITING
A Survey of Maribavir Tablets in Participants With Cytomegalovirus Infection
Lead Sponsor:
Takeda
Conditions:
Cytomegalovirus (CMV)
Eligibility:
All Genders
Brief Summary
This study is a survey in Japan of Maribavir tablets used to treat participants with Cytomegalovirus (CMV) infection refractory to existing anti-CMV therapy in organ transplantation (including hematop...
Eligibility Criteria
Inclusion
- \- All participants with Cytomegalovirus (CMV) infection refractory to existing anti-CMV therapy in organ transplantation (including hematopoietic stem cell transplantation).
Exclusion
- \- None
Key Trial Info
Start Date :
August 28 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 30 2031
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT06577363
Start Date
August 28 2024
End Date
August 30 2031
Last Update
October 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Takeda selected site
Tokyo, Japan